Cancer Research and Treatment

Original Articles

Predictive Value of the nProfiler 1 Assay for the Efficacy of Adjuvant S-1–Based Doublet Chemotherapy in Stage III Gastric Cancer: A Post-Hoc Analysis of a Randomized Phase III Trial: Dong Ki Lee, Choong-kun Lee, Hyo Song Kim, Sun Jin Sym, Dae Young Zang, Ki Hyang Kim, Joo Han Lim, Hae Su Kim, Kyung Hee Lee, Heon Yung Gee, Sun Young Rha, Hyunki Kim, Minkyu Jung; Received July 25, 2024 Accepted November 9, 2024 Published online November 12, 2024; DOI: https://doi.org/10.4143/crt.2024.705 [Epub ahead of print]

Abstract PDF Supplementary Material PubReader ePub: Purpose
The nProfiler 1 Stomach Cancer Assay (nProfiler1), designed to predict responses to fluorouracil-based adjuvant chemotherapy, measures the expression of four gastric cancer target genes (GZMB, WARS, SFRP4, and CDX1). The randomized phase III POST trial aimed to compare the efficacies of two adjuvant S-1-based doublet chemotherapies: S-1 plus cisplatin (SP) and S-1 plus docetaxel (DS). This study aimed to validate the nProfiler1 assay using a distinct cohort from the POST trial.
Materials and Methods
The nProfiler1 assay stratifies patients into three groups (low-risk, intermediate-risk, and high-risk) using the prognostic single-patient classifier and two groups (chemotherapy-benefit and no-benefit) using the predictive single-patient classifier. The nProfiler1 assay was applied to formalin-fixed paraffin-embedded slides obtained from the POST trial. Disease-free survival (DFS) and overall survival (OS), including 5-year survival rates, were calculated for the enrolled patients.
Results
Of the 153 patients in the POST trial, 118 were included in the post-hoc analysis. With a median follow-up of 57.9 months, no significant difference in DFS or OS was observed between the SP and DS groups. The prognostic single-patient classifier predicted the OS in the SP group (p=0.043) but not in the DS group (p=0.594). The chemotherapy-benefit group exhibited numerically longer DFS than the no-benefit group in the SP and DS groups.
Conclusion
The nProfiler1 assay offers valuable insights into the prognosis and efficacy of adjuvant chemotherapy based on fluorouracil plus platinum doublet regimens but not docetaxel-containing regimens. Further validation with larger patient cohorts and different regimens is warranted.

655 View
88 Download

Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer: Min-Young Lee, Bo Mi Ku, Hae Su Kim, Ji Yun Lee, Sung Hee Lim, Jong-Mu Sun, Se-Hoon Lee, Keunchil Park, Young Lyun Oh, Mineui Hong, Han-Sin Jeong, Young-Ik Son, Chung-Hwan Baek, Myung-Ju Ahn; Cancer Res Treat. 2017;49(4):906-914. Published online December 26, 2016; DOI: https://doi.org/10.4143/crt.2016.424

Abstract PDF PubReader ePub

Purpose
Papillary thyroid carcinomas (PTCs) frequently involve genetic alterations. The objective of this study was to investigate genetic alterations and further explore the relationships between these genetic alterations and clinicopathological characteristics in a high-recurrence risk (node positive, N1) PTC group.
Materials and Methods
Tumor tissue blocks were obtained from 240 surgically resected patients with histologically confirmed stage III/IV (pT3/4 or N1) PTCs. We screened gene fusions using NanoString’s nCountertechnology and mutational analysiswas performed by directDNA sequencing.Data describing the clinicopathological characteristics and clinical courses were retrospectively collected.
Results
Of the 240 PTC patients, 207 (86.3%) had at least one genetic alteration, including BRAF mutation in 190 patients (79.2%), PIK3CA mutation in 25 patients (10.4%), NTRK1/3 fusion in six patients (2.5%), and RET fusion in 24 patients (10.0%). Concomitant presence of more than two genetic alterations was seen in 36 patients (15%). PTCs harboring BRAF mutation were associated with RET wild-type expression (p=0.001). RET fusion genes have been found to occur with significantly higher frequency in N1b stage patients (p=0.003) or groups of patients aged 45 years or older (p=0.031); however, no significant correlation was found between other genetic alterations. There was no trend toward favorable recurrence-free survival or overall survival among patients lacking genetic alterations.
Conclusion
In the selected high-recurrence risk PTC group, most patients had more than one genetic alteration. However, these known alterations could not entirely account for clinicopathological features of high-recurrence risk PTC.

Citations

Citations to this article as recorded by

Role of contrast-enhanced ultrasound with time-intensity curve analysis about thyroid nodule and parenchyma for differentiating BRAF V600E mutation status
Zhipeng Hu, Rong Xue, Zhixi Liu, Liang Liu, Zheli Gong
PeerJ.2025; 13: e19006. CrossRef
BRAF V600E mutation co-existing with oncogenic mutations is associated with aggressive clinicopathologic features and poor prognosis in papillary thyroid carcinoma
Nobuyuki Bandoh, Takashi Goto, Yasutaka Kato, Akinobu Kubota, Shota Sakaue, Ryuhei Takeda, Shuto Hayashi, Misaki Hayashi, Shogo Baba, Tomomi Yamaguchi-Isochi, Hiroshi Nishihara, Hajime Kamada
Asian Journal of Surgery.2024; 47(1): 413. CrossRef
FHL1: A novel diagnostic marker for papillary thyroid carcinoma
Yeting Zeng, Dehua Zeng, Xingfeng Qi, Hanxi Wang, Xuzhou Wang, Xiaodong Dai, Lijuan Qu
Pathology International.2024; 74(9): 520. CrossRef
Rearranged During Transfection Rearrangement Detection by Fluorescence In Situ Hybridization Compared With Other Techniques in NSCLC
Anne Mc Leer, Julie Mondet, Nelly Magnat, Mailys Mersch, Diane Giovannini, Camille Emprou, Anne-Claire Toffart, Nathalie Sturm, Sylvie Lantuéjoul, David Benito
JTO Clinical and Research Reports.2024; 5(12): 100714. CrossRef
Essential news for clinical practice—thyroid cancer
Barbara Kiesewetter, Ladislaia Wolff, Markus Raderer
memo - Magazine of European Medical Oncology.2023; 16(1): 47. CrossRef
A new paradigm for epidermal growth factor receptor expression exists in PTC and NIFTP regulated by microRNAs
Abeer Al-Abdallah, Iman Jahanbani, Rola H. Ali, Nabeel Al-Brahim, Jeena Prasanth, Bashayer Al-Shammary, Maie Al-Bader
Frontiers in Oncology.2023;[Epub] CrossRef
NanoString in the screening of genetic abnormalities associated with thyroid cancer
Elisabetta Macerola, Anello Marcello Poma, Fulvio Basolo
Seminars in Cancer Biology.2022; 79: 132. CrossRef
The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with RET alterations
Steve Duff, Francesca Bargiacchi, Chelsea Norregaard, Melanie Brener, Erin Sullivan
Journal of Managed Care & Specialty Pharmacy.2022; 28(2): 218. CrossRef
Thyroid cancer incidence disparities among ethnic Asian American populations, 1990–2014
Alice W. Lee, Roy A. Mendoza, Shehla Aman, Robert Hsu, Lihua Liu
Annals of Epidemiology.2022; 66: 28. CrossRef
Analytical Accuracy of RET Fusion Detection by Break-Apart Fluorescence In Situ Hybridization
Jessica A. Baker, Anthony N. Sireci, Narasimha Marella, Holly Kay Cannon, Tyler J. Marquart, Timothy R. Holzer, Leslie O'Neill Reising, Joel D. Cook, Sameera R. Wijayawardana, Juraj Bodo, Eric D. Hsi, Andrew E. Schade, Gerard J. Oakley
Archives of Pathology & Laboratory Medicine.2022; 146(3): 351. CrossRef
Intratumoral Genetic Heterogeneity in Papillary Thyroid Cancer: Occurrence and Clinical Significance
Laura Fugazzola, Marina Muzza, Gabriele Pogliaghi, Mario Vitale
Cancers.2020; 12(2): 383. CrossRef
The stress-activated protein kinase pathway and the expression of stanniocalcin-1 are regulated by miR-146b-5p in papillary thyroid carcinogenesis
Abeer Al-Abdallah, Iman Jahanbani, Heba Mehdawi, Rola H Ali, Nabeel Al-Brahim, Olusegun Mojiminiyi
Cancer Biology & Therapy.2020; 21(5): 412. CrossRef
Risk Stratification Using a Novel Genetic Classifier IncludingPLEKHS1Promoter Mutations for Differentiated Thyroid Cancer with Distant Metastasis
Chan Kwon Jung, Seung-Hyun Jung, Sora Jeon, Young Mun Jeong, Yourha Kim, Sohee Lee, Ja-Seong Bae, Yeun-Jun Chung
Thyroid.2020; 30(11): 1589. CrossRef
Prediction of cervical lymph node metastasis with contrast-enhanced ultrasound and association between presence of BRAFV600E and extrathyroidal extension in papillary thyroid carcinoma
Jia Zhan, Long-hui Zhang, Qing Yu, Chao-lun Li, Yue Chen, Wen-Ping Wang, Hong Ding
Therapeutic Advances in Medical Oncology.2020;[Epub] CrossRef
Clinical significance of eukaryotic translation initiation factor 5A2 in papillary thyroid cancer
Hongmei Zhang, Kejun Zhang, Liang Ning, Dong Chen, Fengyun Hao, Peng Li
Bioengineered.2020; 11(1): 1325. CrossRef
High Preponderance of BRAF V600E Mutation in Papillary Thyroid Carcinoma Among Filipinos: A Clinicopathologic Study
Gerard Anthony M. Espiritu, Joemari T. Malana, Arlie Jean Grace V. Dumasis, Daphne C. Ang
Journal of Global Oncology.2019; (5): 1. CrossRef
PIK3CA Gene Mutations in Solid Malignancies: Association with Clinicopathological Parameters and Prognosis
Ali Alqahtani, Hazem S. K. Ayesh, Hafez Halawani
Cancers.2019; 12(1): 93. CrossRef
Targeted next‑generation sequencing of cancer‑related genes in thyroid carcinoma: A single institution's experience
Nobuyuki Bandoh, Toshiaki Akahane, Takashi Goto, Michihisa Kono, Haruyuki Ichikawa, Takahiro Sawada, Tomomi Yamaguchi, Hiroshi Nakano, Yumiko Kawase, Yasutaka Kato, Hajime Kamada, Yasuaki Harabuchi, Kazuo Shimizu, Hiroshi Nishihara
Oncology Letters.2018;[Epub] CrossRef
Niclosamide induces apoptosis through mitochondrial intrinsic pathway and inhibits migration and invasion in human thyroid cancer in vitro
Kai Yu, Tingting Wang, Yujue Li, Chun Wang, Xia Wang, Mei Zhang, Yongmei Xie, Shuangqing Li, Zhenmei An, Tinghong Ye
Biomedicine & Pharmacotherapy.2017; 92: 403. CrossRef

11,382 View
371 Download
20 Web of Science
19 Crossref

Clinicopathologic Features and Long-Term Outcomes of Elderly Breast Cancer Patients: Experiences at a Single Institution in Korea: Hee Kyung Kim, Jun Soo Ham, Seonggyu Byeon, Kwai Han Yoo, Ki Sun Jung, Haa-Na Song, Jinhyun Cho, Ji Yun Lee, Sung Hee Lim, Hae Su Kim, Ji-Yeon Kim, Jeong Eon Lee, Seok Won Kim, Seok Jin Nam, Se Kyung Lee, Soo Youn Bae, Jin Seok Ahn, Young-Hyuck Im, Yeon Hee Park; Cancer Res Treat. 2016;48(4):1382-1388. Published online March 11, 2016; DOI: https://doi.org/10.4143/crt.2015.423

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to assess the tumor characteristics and long-term clinical outcomes of adjuvant treatments after surgery with a curative aim for patients with breast cancer who are 65 years and older. Materials and Methods Patients with breast cancer who underwent curative surgery from 2000 to 2009 were analyzed (n=4,388). Tumor characteristics and survival outcome were compared by dividing the patients into two age groups (< 65 and ≥ 65 years old). The Kaplan-Meier method was used for comparison of survival rates by log-rank test, and a Cox regression model was used to examine the effect of variables.
Results
Among 4,388 patients with invasive breast cancer, 317 patients (7.2%) were 65 years or older and the median age of all patients was 47 years (range, 18 to 91 years). Tumor characteristics were similar between the two age groups, but the older patients were treated less often with adjuvant treatments. During a median follow-up period of 122 months, recurrence-free survival (RFS) was equivalent for patients 65 years and older compared to younger patients, but significantly worse in overall survival (OS) and breast cancer–specific survival (BCSS) (5-year OS, 94.3% vs. 90.5%; p < 0.001 and 5-year BCSS, 94.7% vs. 91.8%; p=0.031). In the multivariate model, age ≥ 65 years old was identified as an independent risk factor for OS and RFS. Conclusion Elderly breast cancer appeared to have worse outcomes with very low prevalence in Korea, despite similar tumor characteristics. More active adjuvant therapies would have a role for aggressive subtypes for fit, elderly patients.

Citations

Citations to this article as recorded by

HISTOPATHOLOGICAL AND BIOLOGICAL BEHAVIOR OF BREAST CANCER IN ELDERLY KURDISH WOMEN
Kamal Saeed, Shewaz Salih
JOURNAL OF SULAIMANI MEDICAL COLLEGE.2023; 13(4): 11. CrossRef
Analysis of the tumor characteristics in young age breast cancer patients using collaborative stage data of the Korea Central Cancer Registry
Junyup Kim, Seri Hong, Jae Jun Lee, Young-Joo Won, Eun Sook Lee, Han-Sung Kang, Seeyoun Lee, Jai Hong Han, Eun-Gyeong Lee, Heein Jo, Hyun Hee Kim, So-Youn Jung
Breast Cancer Research and Treatment.2021; 187(3): 785. CrossRef
Survival outcomes in elderly Taiwanese women according to breast cancer subtype and lymph node status: A single-center retrospective study
Kung-Hung Lin, Huan-Ming Hsu, Kuo-Feng Hsu, Chi-Hong Chu, Zhi-Jie Hong, Chun-Yu Fu, Yu-Ching Chou, Golshan Mehra, Ming-Shen Dai, Jyh-Cherng Yu, Guo-Shiou Liao, Jason Chia-Hsun Hsieh
PLOS ONE.2021; 16(12): e0261258. CrossRef
Could lymph node evaluation be eliminated in nearly 50% of women with early stage ER/PR positive breast cancer?
Juan Ruiz, Gerson Maldonado, Elizabeth Ablah, Hayrettin Okut, Jared Reyes, Karson Quinn, Patty L. Tenofsky
The American Journal of Surgery.2020; 220(6): 1417. CrossRef
Overall survival of elderly patients with breast cancer is not related to breast-cancer specific survival: A single institution experience in Japan
Haruko Takuwa, Wakako Tsuji, Fumiaki Yotsumoto
Breast Disease.2018; 37(4): 177. CrossRef
Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting
Chiara Mandoj, Laura Pizzuti, Domenico Sergi, Isabella Sperduti, Marco Mazzotta, Luigi Di Lauro, Antonella Amodio, Silvia Carpano, Anna Di Benedetto, Claudio Botti, Francesca Ferranti, Anna Antenucci, Maria Gabriella D’Alessandro, Paolo Marchetti, Silveri
Journal of Translational Medicine.2018;[Epub] CrossRef
Do site and type of metastasis in breast cancer show a changing pattern with increased age? A cross comparison of clinicopathological characteristics between age groups
Majid Akrami, Afrooz Sepahdar, Peyman Arasteh, Sedigheh Tahmasebi, Vahid Zangouri, Azam Askari, Babak Pezeshki, Abdolrasoul Talei
World Journal of Surgical Oncology.2018;[Epub] CrossRef
Predicting Nodal Positivity in Women 70 Years of Age and Older with Hormone Receptor-Positive Breast Cancer to Aid Incorporation of a Society of Surgical Oncology Choosing Wisely Guideline into Clinical Practice
Jessemae L. Welsh, Tanya L. Hoskin, Courtney N. Day, Elizabeth B. Habermann, Matthew P. Goetz, Judy C. Boughey
Annals of Surgical Oncology.2017; 24(10): 2881. CrossRef
Combination of 125I brachytherapy and chemotherapy for unresectable recurrent breast cancer
Qixing Tan, Qinghong Qin, Weiping Yang, Bin Lian, Qinguo Mo, Changyuan Wei
Medicine.2016; 95(44): e5302. CrossRef

12,912 View
156 Download
8 Web of Science
9 Crossref

Association between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma: Hae Su Kim, Ji Yun Lee, Sung Hee Lim, Keunchil Park, Jong-Mu Sun, Young Hyeh Ko, Chung-Hwan Baek, Young-ik Son, Han Sin Jeong, Yong Chan Ahn, Min-Young Lee, Mineui Hong, Myung-Ju Ahn; Cancer Res Treat. 2016;48(2):527-536. Published online September 15, 2015; DOI: https://doi.org/10.4143/crt.2015.249

Abstract PDF PubReader ePub

Purpose
Oropharyngeal squamous cell carcinoma (OSCC) has been recognized as an immunosuppressive disease. Various mechanisms have been proposed for immune escape, including dysregulation of immune checkpoints such as the PD-1:PD-L1 pathway. We investigated the expression of programmed cell death-ligand 1 (PD-L1) in HPV-negative and HPV-positive OSCC to determine its prevalence and prognostic relevance.
Materials and Methods
Using immunohistochemistry, 133 cases of OSCC were evaluated for expression of PD-L1. Formalin-fixed paraffin-embedded tumor samples were stained with monoclonal antibody (clone 5H1) to PD-L1. PD-L1 positivity was defined as membrane staining in ≥20% of tumor cells. Correlations between PD-L1 expression and HPV status and survival parameters were analyzed.
Results
Of the 133 patients, 68% showed PD-L1 expression, and 67% of patients were positive for p16 expression by immunohistochemistry. No significant difference in PD-L1 expression was observed between HPV(-) and HPV(+) tumors (61% vs. 71%, p=0.274). No significant difference in age, gender, smoking history, location of tumor origin, or stage was observed according to PD-L1 status. With a median follow-up period of 44 months, older age (≥65) (p=0.017) and T3-4 stage (p<0.001) were associated with poor overall survival (OS), whereas PD-L1 expression did not affect OS in univariate and multivariate analysis.
Conclusion
PD-L1 expression was observed in the majority of OSCC patients regardless of HPV status. Further large prospective studies are required to determine the role of PD-L1 expression as a prognostic or predictive biomarker, and clinical studies of immune checkpoint inhibitors in OCSS are warranted regardless of HPV status.

Citations

Citations to this article as recorded by

A bibliometric analysis of immune response in oral cancer
Rongrong Zhang, Runying Guo, Yuqi Xin, Qingkun Jiang, Jiaxuan Qiu
Discover Oncology.2025;[Epub] CrossRef
HPV frequency in oral cavity and oropharynx cancers and its association with immune checkpoint inhibitors
Hayriye Tatlı Doğan, Mustafa Tahtacı
Türk Tıp Dergisi.2025; 10(1): 1. CrossRef
Treatment Outcomes of Squamous Cell Carcinoma of the Soft Palate and the Prognostic Significance of HPV/p16 Status
Meng‐hua Li, Xing Zhang, Feng‐jiao Li, Xian‐lu Gao, Shi‐da Yan, Qiao‐hong Lin, Xi‐yuan Li, Jian Meng, Ying Zhang, Shi‐ting Zhang, Shu‐wei Chen, Ming Song
Head & Neck.2025;[Epub] CrossRef
Prognostic role of PD-L1 expression in head and neck squamous cell carcinoma: An institutional experience from India
Pooja Sharma Kala, Naveen Thapliyal, Bhawna Pant, Nitin Sharma, Hari Shankar Pandey
Pathology - Research and Practice.2024; 254: 155133. CrossRef
Référentiel national de traitement des carcinomes épidermoïdes des voies aérodigestives supérieures – Principes généraux de traitement
Béatrix Barry, Gilles Dolivet, Florian Clatot, Florence Huguet, Cyril Abdeddaim, Bertrand Baujat, Nicolas Blanchard, Gilles Calais, Xavier Carrat, Anne Chatellier, Florence Coste, Didier Cupissol, Philippe Cuvelier, Erwan De Mones Del Pujol, Sophie Deneuv
Bulletin du Cancer.2024; 111(4): 393. CrossRef
PD-L1 expression in head and neck squamous cell carcinoma and its clinical significance: A prospective observational study from a tertiary care centre
Sindhu Kilaru, Soumya Surath Panda, Lalatendu Moharana, Debahuti Mohapatra, Satya Sundar G. Mohapatra, Adyakinkar Panda, Spoorthy Kolluri, Suma Devaraj, Ananya Kabi, Bharat Das, Ghanashyam Biswas
Journal of Cancer Research and Therapeutics.2024; 20(1): 46. CrossRef
Histologic and Genomic Analysis of Conjunctival SCC in African and American Cohorts Reveal UV Light and HPV Signatures and High Tumor Mutation Burden
Frederico O. Gleber-Netto, Priyadharsini Nagarajan, Oded Sagiv, Curtis R. Pickering, Neil Gross, Jing Ning, Melisachew M. Yeshi, Yonas Mitku, Michael T. Tetzlaff, Bita Esmaeli
Investigative Opthalmology & Visual Science.2024; 65(4): 24. CrossRef
Considerable interlaboratory variation in PD‐L1 positivity for head and neck squamous cell carcinoma in the Netherlands— A nationwide evaluation study
Maaike Anna Hempenius, Bregje M Koomen, Ivette A G Deckers, Sjoukje F Oosting, Stefan M Willems, Bert van der Vegt
Histopathology.2024; 85(1): 133. CrossRef
The Role of Estrogen and Estrogen Receptors in Head and Neck Tumors
Jacqueline-Katrin Kranjčević, Josipa Čonkaš, Petar Ozretić
Cancers.2024; 16(8): 1575. CrossRef
PD-L1 Expression and Its Association With p16 in Head and Neck Squamous Cell Carcinoma in Southwestern Uganda
Rita Nabulya, Raymond Atwine, Brian Ssenkumba, Yekosani Mitala, Jamilah Nabukenya
Pathology and Laboratory Medicine International.2024; Volume 16: 1. CrossRef
High‐risk HPV oncoproteins E6 and E7 and their interplay with the innate immune response: Uncovering mechanisms of immune evasion and therapeutic prospects
Irene Lo Cigno, Federica Calati, Carlo Girone, Marta Catozzo, Marisa Gariglio
Journal of Medical Virology.2024;[Epub] CrossRef
PD-L1 immunohistochemical expression considering HPV status in oropharyngeal squamous cell carcinoma
Raíssa Soares dos ANJOS, Marianne de Vasconcelos CARVALHO, Rayanna Thayse Florêncio COSTA, Belmiro Cavalcanti do Egito VASCONCELOS, Sandra Lúcia Dantas MORAES, Eduardo Piza PELLIZZER
Brazilian Oral Research.2024;[Epub] CrossRef
PD-1 and PD-L1 Expression Levels as a Potential Biomarker of Chronic Rhinosinusitis and Head and Neck Cancers
Katarzyna Malinowska, Andrzej Kowalski, Anna Merecz-Sadowska, Milena Paprocka-Zjawiona, Przemysław Sitarek, Tomasz Kowalczyk, Hanna Zielińska-Bliźniewska
Journal of Clinical Medicine.2023; 12(5): 2033. CrossRef
Immunotherapy in oral cancer: Review
Despoina Papaioannou, Spyridoula Petsali, Alida Ndreou, Fani Akritidou, Vasileios Zisis, Dimitrios Kavvadas, Athanasios Poulopoulos, Sofia Karachrysafi, Dimitrios Andreadis
Balkan Journal of Dental Medicine.2023; 27(3): 129. CrossRef
Programmed Death Ligand-1 Combined Positive Score Concordance and Interrater Reliability in Primary Tumors and Synchronous Lymph Node Metastases in Resected Cases of p16+ Oropharyngeal Squamous Cell Carcinoma
Amandeep Kaur, Kristine Kuchta, William Watkin, Megan Sullivan, Lin Liu, Pouya Jamshidi, Nick Campbell, Bruce Brockstein, Ajit Paintal
Archives of Pathology & Laboratory Medicine.2023; 147(4): 442. CrossRef
Expression of immune checkpoint protein in oral squamous cell carcinoma and its clinicopathological correlation: A tertiary care center cross-sectional study
Sonal Ratnakar, Madhu Kumar, Malti K. Maurya, Sumaira Qayoom, Mala Sagar, Suresh Babu, Vijay Kumar
Journal of Oral and Maxillofacial Pathology.2023; 27(3): 597. CrossRef
Commentary on “Clinicopathological features of programmed cell death-ligand 1 expression in patients with oral squamous cell carcinoma”
Juan Francisco Peña-Cardelles, José Ernesto Moro-Rodríguez, José Luís Cebrián-Carretero, José Juan Pozo-Kreilinger
Open Medicine.2022; 17(1): 227. CrossRef
Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta-Analysis
Ramy R. Saleh, Jordan L. Scott, Nicholas Meti, Danielle Perlon, Rouhi Fazelzad, Alberto Ocana, Eitan Amir
Molecular Diagnosis & Therapy.2022; 26(2): 153. CrossRef
Immunotherapy for head and neck cancer: Present and future
Morena Fasano, Carminia Maria Della Corte, Raimondo Di Liello, Giuseppe Viscardi, Francesca Sparano, Maria Lucia Iacovino, Fernando Paragliola, Antonio Piccolo, Stefania Napolitano, Giulia Martini, Floriana Morgillo, Salvatore Cappabianca, Fortunato Ciard
Critical Reviews in Oncology/Hematology.2022; 174: 103679. CrossRef
Differences in PD-L1 Expression between oral and oropharyngeal squamous cell carcinoma
Sebastian Blatt, Maximilian Krüger, Constantin Rump, Stefanie Zimmer, Keyvan Sagheb, Julian Künzel, Afsheen Raza
PLOS ONE.2022; 17(5): e0269136. CrossRef
Expression of PD-L1 is HPV/P16-independent in oral squamous cell carcinoma
Kit Kitichotkul, Nirush Lertprasertsuke, Sompid Kintarak, Surawut Pongsiriwet, Warit Powcharoen, Anak Iamaroon
Heliyon.2022; 8(10): e10667. CrossRef
Survival Outcomes of Complete Pulmonary Metastasectomy for Head and Neck Squamous Cell Carcinomas
Hiroaki Kuroda, Shin Koyama, Mingyon Mun, Jun Nakajima, Kazuhito Funai, Ichiro Yoshino, Yoshikane Yamauchi, Masafumi Kawamura
Cancer Management and Research.2022; Volume 14: 3095. CrossRef
Expression of PD-L1 is HPV/P16-Independent in Oral Squamous Cell Carcinoma
Kit Kitichotkul, Nirush Lertprasertsuke, Sompid Kintarak, Surawut Pongsiriwet, Warit Powcharoen, Anak Iamaroon
SSRN Electronic Journal .2022;[Epub] CrossRef
CMTM6 and PD-1/PD-L1 overexpression is associated with the clinical characteristics of malignancy in oral squamous cell carcinoma
Songtao Zhang, Qiujie Yan, Song Wei, Xiaobo Feng, Miaomiao Xue, Lina Liu, Jili Cui, Yuanyuan Zhang
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology.2021; 132(2): 202. CrossRef
PD-L1 expression in anogenital and oropharyngeal squamous cell carcinomas associated with different clinicopathological features, HPV status and prognosis: a meta-analysis
Yuan Qin, Jiaochen Luan, Xiang Zhou, Ying Li
Bioscience Reports.2021;[Epub] CrossRef
Resistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors
Parmida Sadat Pezeshki, Pouya Mahdavi Sharif, Nima Rezaei
Expert Opinion on Biological Therapy.2021; 21(12): 1575. CrossRef
PD-L1 TESTING AND IMMUNOTHERAPY SELECTION – EARLY LABORATORY EXPERIENCE AND ITS POTENTIAL ROLE IN HEAD AND NECK CANCER MANAGEMENT
Bancu Bancu, Richard Cowan, Anshuman Chaturvedi
Archive of Clinical Cases.2021; 8(1): 14. CrossRef
Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus
Huanhuan Wang, Qin Zhao, Yuyu Zhang, Qihe Zhang, Zhuangzhuang Zheng, Shiyu Liu, Zijing Liu, Lingbin Meng, Ying Xin, Xin Jiang
Frontiers in Immunology.2021;[Epub] CrossRef
The effects of PD-1/PD-L1 checkpoint inhibitors on recurrent/metastatic head and neck squamous cell carcinoma: a critical review of the literature and meta-analysis
Emily Clarke, Jesper Grau Eriksen, Sarah Barrett
Acta Oncologica.2021; 60(11): 1534. CrossRef
Distinct immune microenvironment profiles of therapeutic responders emerge in combined TGFβ/PD-L1 blockade-treated squamous cell carcinoma
Alexander A. Strait, Rachel A. Woolaver, Spencer C. Hall, Christian D. Young, Sana D. Karam, Antonio Jimeno, Yan Lan, David Raben, Jing H. Wang, Xiao-Jing Wang
Communications Biology.2021;[Epub] CrossRef
Commentary on 'Relationship of programmed death ligand-1 expression with clinicopathological features and prognosis in patients with oral squamous cell carcinoma: A meta-analysis' (He et al., (2020) Archives of Oral Biology, 114, 104717)
Juan Francisco Peña-Cardelles, José Ernesto Moro-Rodríguez, José Luís Cebrián-Carretero, José Juan Pozo-Kreilinger
Archives of Oral Biology.2021; 132: 105274. CrossRef
Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma
Kimberly M. Burcher, Jeffrey W. Lantz, Elena Gavrila, Arianne Abreu, Jack T. Burcher, Andrew T. Faucheux, Amy Xie, Clayton Jackson, Alexander H. Song, Ryan T. Hughes, Thomas Lycan, Paul M. Bunch, Cristina M. Furdui, Umit Topaloglu, Ralph B. D’Agostino, We
Cancers.2021; 13(22): 5733. CrossRef
Prognostic Significance of PD-L1 Expression In Patients With Primary Oropharyngeal Squamous Cell Carcinoma: A Meta-Analysis
Jerry Polesel, Anna Menegaldo, Giancarlo Tirelli, Vittorio Giacomarra, Roberto Guerrieri, Lorena Baboci, Mariateresa Casarotto, Valentina Lupato, Giuseppe Fanetti, Paolo Boscolo-Rizzo, Elisabetta Fratta
Frontiers in Oncology.2021;[Epub] CrossRef
Tumor Immunity and Immunotherapy for HPV-Related Cancers
Achraf A. Shamseddine, Bharat Burman, Nancy Y. Lee, Dmitriy Zamarin, Nadeem Riaz
Cancer Discovery.2021; 11(8): 1896. CrossRef
An update of knowledge on PD‐L1 in head and neck cancers: Physiologic, prognostic and therapeutic perspectives
Daniel Lenouvel, Miguel Ángel González‐Moles, Asmae Talbaoui, Pablo Ramos‐García, Lucía González‐Ruiz, Isabel Ruiz‐Ávila, José Antonio Gil‐Montoya
Oral Diseases.2020; 26(3): 511. CrossRef
A treatise on endothelial biology and exosomes: homage to Theresa Maria Listowska Whiteside
N. Ludwig, M. T. Lotze
HNO.2020; 68(2): 71. CrossRef
PD-L1 expression and survival in p16-negative and -positive squamous cell carcinomas of the vulva
Bastian Czogalla, Deborah Pham, Fabian Trillsch, Miriam Rottmann, Julia Gallwas, Alexander Burges, Sven Mahner, Thomas Kirchner, Udo Jeschke, Doris Mayr, Elisa Schmoeckel
Journal of Cancer Research and Clinical Oncology.2020; 146(3): 569. CrossRef
Prognostic impact of PD-L1 in oropharyngeal cancer after primary curative radiotherapy and relation to HPV and tobacco smoking
Jacob K. Lilja-Fischer, Jesper G. Eriksen, Jeanette B. Georgsen, Thao T. Vo, Stine R. Larsen, Jonathan Cheng, Michael Busch-Sørensen, Deepti Aurora-Garg, Torben Steiniche, Jens Overgaard
Acta Oncologica.2020; 59(6): 666. CrossRef
Immunologic impact of chemoradiation in cervical cancer and how immune cell infiltration could lead toward personalized treatment
Lien Lippens, Mieke Van Bockstal, Emiel A. De Jaeghere, Philippe Tummers, Amin Makar, Sofie De Geyter, Koen Van de Vijver, An Hendrix, Katrien Vandecasteele, Hannelore Denys
International Journal of Cancer.2020; 147(2): 554. CrossRef
Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer
Victor C. Kok
Frontiers in Oncology.2020;[Epub] CrossRef
The different role of PD-L1 in head and neck squamous cell carcinomas: A meta-analysis
Hui Tang, Xiang Zhou, Yu Ye, Yi Zhou, Chengyu Wu, Yan Xu
Pathology - Research and Practice.2020; 216(1): 152768. CrossRef
Relationship of programmed death ligand-1 expression with clinicopathological features and prognosis in patients with oral squamous cell carcinoma: A meta-analysis
Jing He, Xiao-Fang Chen, Ming-Gao Xu, Jing Zhao
Archives of Oral Biology.2020; 114: 104717. CrossRef
The role of transforming growth factor‐beta in immune suppression and chronic inflammation of squamous cell carcinomas
Alexander A. Strait, Xiao‐Jing Wang
Molecular Carcinogenesis.2020; 59(7): 745. CrossRef
The roles of programmed death ligand 1 in virus-associated cancers
Morvarid Golrokh Mofrad, Donya Taghizadeh Maleki, Ebrahim Faghihloo
Infection, Genetics and Evolution.2020; 84: 104368. CrossRef
Clinicopathological features of programmed cell death-ligand 1 expression in patients with oral squamous cell carcinoma
Yong-Xin Cui, Xian-Shuang Su
Open Medicine.2020; 15(1): 292. CrossRef
The tumor immune microenvironment and its implications for clinical outcome in patients with oropharyngeal squamous cell carcinoma
Dominik Gurin, Marek Slavik, Marketa Hermanova, Iveta Selingerova, Tomas Kazda, Michal Hendrych, Tetiana Shatokhina, Marcela Vesela
Journal of Oral Pathology & Medicine.2020; 49(9): 886. CrossRef
PD-L1 Expression and a High Tumor Infiltrate of CD8+ Lymphocytes Predict Outcome in Patients with Oropharyngeal Squamous Cells Carcinoma
Nora Wuerdemann, Sibel E. Gültekin, Katharina Pütz, Claus Wittekindt, Christian U. Huebbers, Shachi J. Sharma, Hans Eckel, Anna B. Schubotz, Stefan Gattenlöhner, Reinhard Büttner, Ernst-Jan Speel, Jens P. Klussmann, Steffen Wagner, Alexander Quaas
International Journal of Molecular Sciences.2020; 21(15): 5228. CrossRef
Evaluation of p16 in Epithelial Ovarian Cancer for a 10-Year Study in Northeast China: Significance of HPV in Correlation with PD-L1 Expression

Xinxin Yang, Qi You, Guodong Yao, Jingshu Geng, Rong Ma, Hongxue Meng
Cancer Management and Research.2020; Volume 12: 6747. CrossRef
Prevalence of high-risk human papillomavirus and its genotype distribution in head and neck squamous cell carcinomas
Yuil Kim, Young-Hoon Joo, Min-Sik Kim, Youn Soo Lee
Journal of Pathology and Translational Medicine.2020; 54(5): 411. CrossRef
The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer
Xin-wei Qiao, Jian Jiang, Xin Pang, Mei-chang Huang, Ya-jie Tang, Xin-hua Liang, Ya-ling Tang
Frontiers in Immunology.2020;[Epub] CrossRef
Immune Escape Mechanisms and Their Clinical Relevance in Head and Neck Squamous Cell Carcinoma
Barbara Seliger, Chiara Massa, Bo Yang, Daniel Bethmann, Matthias Kappler, Alexander Walter Eckert, Claudia Wickenhauser
International Journal of Molecular Sciences.2020; 21(19): 7032. CrossRef
PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma
D. Evrard, M. Hourseau, A. Couvelard, V. Paradis, H. Gauthier, E. Raymond, C. Halimi, B. Barry, S. Faivre
OncoImmunology.2020;[Epub] CrossRef
Expression of immunoregulatory molecules PD-L1 and PD-1 in oral cancer and precancerous lesions: A cohort study of Japanese patients
Atsumu Kouketsu, Ikuro Sato, Mariko Oikawa, Yoshinaka Shimizu, Hiroki Saito, Tetsu Takahashi, Hiroyuki Kumamoto
Journal of Cranio-Maxillofacial Surgery.2019; 47(1): 33. CrossRef
The value of immunotherapy in head and neck cancer
Paolo Manca, Luis E. Raez, Matthew Salzberg, Jorge Sanchez, Brian Hunis, Christian Rolfo
Expert Opinion on Biological Therapy.2019; 19(1): 35. CrossRef
Oral and Oropharyngeal squamous cell carcinoma: prognostic and predictive parameters in the etiopathogenetic route
Iacopo Panarese, Gabriella Aquino, Andrea Ronchi, Francesco Longo, Marco Montella, Immacolata Cozzolino, Giuseppe Roccuzzo, Giuseppe Colella, Michele Caraglia, Renato Franco
Expert Review of Anticancer Therapy.2019; 19(2): 105. CrossRef
The Double-Edged Sword—How Human Papillomaviruses Interact With Immunity in Head and Neck Cancer
Hao-fan Wang, Sha-sha Wang, Ya-Jie Tang, Yu Chen, Min Zheng, Ya-ling Tang, Xin-hua Liang
Frontiers in Immunology.2019;[Epub] CrossRef
The protective role of carnosic acid in ischemic/reperfusion injury through regulation of autophagy under T2DM
Min Hu, Tianyu Li, Zixiang Bo, Feixiang Xiang
Experimental Biology and Medicine.2019; 244(7): 602. CrossRef
Clinical impact of PD-L1 and PD-1 expression in squamous cell cancer of the vulva
Fabinshy Thangarajah, Bernd Morgenstern, Caroline Pahmeyer, Lars Mortimer Schiffmann, Julian Puppe, Peter Mallmann, Stefanie Hamacher, Reinhard Buettner, Christina Alidousty, Barbara Holz, Andreas H. Scheel, Anne Maria Schultheis
Journal of Cancer Research and Clinical Oncology.2019; 145(6): 1651. CrossRef
The emergence of long-term survivors in recurrent and metastatic squamous cell head and neck cancer
Florian Castet, Jesús Brenes, Miren Taberna, Ricard Mesía
Current Opinion in Oncology.2019; 31(3): 160. CrossRef
PYHIN genes as potential biomarkers for prognosis of human papillomavirus-positive or -negative head and neck squamous cell carcinomas
Giuseppe Riva, Giancarlo Pecorari, Matteo Biolatti, Sara Pautasso, Irene Lo Cigno, Massimiliano Garzaro, Valentina Dell’Oste, Santo Landolfo
Molecular Biology Reports.2019; 46(3): 3333. CrossRef
PD-L1/PD1 Expression, Composition of Tumor-Associated Immune Infiltrate, and HPV Status in Conjunctival Squamous Cell Carcinoma
Priyadharsini Nagarajan, Christian El-Hadad, Stephen K. Gruschkus, Jing Ning, Courtney W. Hudgens, Oded Sagiv, Neil Gross, Michael T. Tetzlaff, Bita Esmaeli
Investigative Opthalmology & Visual Science.2019; 60(6): 2388. CrossRef
PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma
Yui Hirata-Nozaki, Takayuki Ohkuri, Kenzo Ohara, Takumi Kumai, Marino Nagata, Shohei Harabuchi, Akemi Kosaka, Toshihiro Nagato, Kei Ishibashi, Kensuke Oikawa, Naoko Aoki, Mizuho Ohara, Yasuaki Harabuchi, Yuji Uno, Hidehiro Takei, Esteban Celis, Hiroya Kob
Journal of Translational Medicine.2019;[Epub] CrossRef
転移・再発頭頸部がんに対する分子標的薬と免疫チェックポイント阻害薬のエビデンス

Nippon Jibiinkoka Gakkai Kaiho.2019; 122(6): 848. CrossRef
Prognostic Value of Combined Programmed Cell Death 1 Ligand and p16 Expression Predicting Responsiveness to Radiotherapy in Patients with Oropharyngeal Squamous Cell Carcinoma
Minsu Kwon, Dae Hwan Kim, Ki Ju Cho, Youngchul Kim, Jin Pyeong Kim, Bae Kwon Jeong, Jong Sil Lee, Ji-Hyun Seo, Jung Je Park
Korean Journal of Otorhinolaryngology-Head and Neck Surgery.2019; 62(12): 712. CrossRef
Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma
Valerie Cristina, Ruth Gabriela Herrera-Gómez, Petr Szturz, Vittoria Espeli, Marco Siano
International Journal of Molecular Sciences.2019; 20(21): 5399. CrossRef
The expression of PD-L1 in salivary gland carcinomas
Domenic Vital, Kristian Ikenberg, Holger Moch, Matthias Rössle, Gerhard F. Huber
Scientific Reports.2019;[Epub] CrossRef
Prognostic value of immune checkpoint molecules in head and neck cancer: a meta-analysis
Yi-Qun Jia, Bo Yang, Li-Ling Wen, Wen-Xin Mu, Zhi Wang, Bin Cheng
Aging.2019; 11(2): 501. CrossRef
Targeting the EGFR and Immune Pathways in Squamous Cell Carcinoma of the Head and Neck (SCCHN): Forging a New Alliance
Nabil F. Saba, Zhuo Gerogia Chen, Missak Haigentz, Paolo Bossi, Alessandra Rinaldo, Juan P. Rodrigo, Antti A. Mäkitie, Robert P. Takes, Primoz Strojan, Jan B. Vermorken, Alfio Ferlito
Molecular Cancer Therapeutics.2019; 18(11): 1909. CrossRef
PD-L1 Expression in Tumor Cells Is an Independent Unfavorable Prognostic Factor in Oral Squamous Cell Carcinoma
Juan C. de Vicente, Tania Rodríguez-Santamarta, Juan P. Rodrigo, Verónica Blanco-Lorenzo, Eva Allonca, Juana M. García-Pedrero
Cancer Epidemiology, Biomarkers & Prevention.2019; 28(3): 546. CrossRef
Beyond the Percentages of PD-L1-Positive Tumor Cells: Induced Versus Constitutive PD-L1 Expression in Primary and Metastatic Head and Neck Squamous Cell Carcinoma
Theresa Scognamiglio, Yao-Tseng Chen
Head and Neck Pathology.2018; 12(2): 221. CrossRef
The Current State of Biological and Clinical Implications of Human Papillomavirus-Related Oropharyngeal Cancer
Shao Hui Huang, Brian O'Sullivan, John Waldron
Seminars in Radiation Oncology.2018; 28(1): 17. CrossRef
Implications of the tumor immune microenvironment for staging and therapeutics
Janis M Taube, Jérôme Galon, Lynette M Sholl, Scott J Rodig, Tricia R Cottrell, Nicolas A Giraldo, Alexander S Baras, Sanjay S Patel, Robert A Anders, David L Rimm, Ashley Cimino-Mathews
Modern Pathology.2018; 31(2): 214. CrossRef
Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments
Benjamin Solomon, Richard J. Young, Danny Rischin
Seminars in Cancer Biology.2018; 52: 228. CrossRef
Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs
Stefano Cavalieri, Licia Rivoltini, Cristiana Bergamini, Laura D. Locati, Lisa Licitra, Paolo Bossi
Cancer Treatment Reviews.2018; 65: 78. CrossRef
Clinical implication of programmed cell death-1 ligand-1 expression in tonsillar squamous cell carcinoma in association with intratumoral heterogeneity, human papillomavirus, and epithelial-to-mesenchymal transition
Mi Jung Kwon, Young-Soo Rho, Eun Sook Nam, Seong Jin Cho, Hye-Rim Park, Soo Kee Min, Jinwon Seo, Ji-Young Choe, Eun Soo Kim, Bumjung Park, Mineui Hong, Kyueng-Whan Min
Human Pathology.2018; 80: 28. CrossRef
The Role of the Programmed Death Receptor-1/Programmed Death Ligand-1: Immunologic Checkpoint in Human Papillomavirus–Associated Head and Neck Squamous Cell Carcinoma
Christine Kunkle, Flavia G Rosado
Archives of Pathology & Laboratory Medicine.2018; 142(6): 719. CrossRef
Genomic Landscapes of EBV-Associated Nasopharyngeal Carcinoma vs. HPV-Associated Head and Neck Cancer
Hoi-Lam Ngan, Lan Wang, Kwok-Wai Lo, Vivian Wai Yan Lui
Cancers.2018; 10(7): 210. CrossRef
PD‐1 and PD‐L1 expression in HNSCC primary cancer and related lymph node metastasis – impact on clinical outcome
Sven Schneider, Lorenz Kadletz, Robert Wiebringhaus, Lukas Kenner, Edgar Selzer, Thorsten Füreder, Orsolya Rajky, Anna S Berghoff, Matthias Preusser, Gregor Heiduschka
Histopathology.2018; 73(4): 573. CrossRef
The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis
Wei-fa Yang, May C.M. Wong, Peter J. Thomson, Kar-Yan Li, Yu-xiong Su
Oral Oncology.2018; 86: 81. CrossRef
Prognostic value of PD -L1 expression in patients with primary solid tumors
Xiao Xiang, Peng-Cheng Yu, Di Long, Xiao-Li Liao, Sen Zhang, Xue-Mei You, Jian-Hong Zhong, Le-Qun Li
Oncotarget.2018; 9(4): 5058. CrossRef
Drug-Sensitivity Screening and Genomic Characterization of 45 HPV-Negative Head and Neck Carcinoma Cell Lines for Novel Biomarkers of Drug Efficacy
Tatiana Lepikhova, Piia-Riitta Karhemo, Riku Louhimo, Bhagwan Yadav, Astrid Murumägi, Evgeny Kulesskiy, Mikko Kivento, Harri Sihto, Reidar Grénman, Stina M. Syrjänen, Olli Kallioniemi, Tero Aittokallio, Krister Wennerberg, Heikki Joensuu, Outi Monni
Molecular Cancer Therapeutics.2018; 17(9): 2060. CrossRef
Immune check point inhibitors for head and neck cancer
Naomi Kiyota
Toukeibu Gan.2018; 44(4): 336. CrossRef
Immune check point inhibitors for head and neck cancer and its proper management on utilizing head and neck cancer collaborative program
Naomi Kiyota
Journal of Japanese Society of Oral Oncology.2018; 30(4): 144. CrossRef
Is There Evidence for the Presence and Relevance of the PD-1/PD-L1 Pathway in Oral Squamous Cell Carcinoma? Hints From an Immunohistochemical Study
Matthias Troeltzsch, Timothy Woodlock, Alix Pianka, Sven Otto, Markus Troeltzsch, Michael Ehrenfeld, Thomas Knösel
Journal of Oral and Maxillofacial Surgery.2017; 75(5): 969. CrossRef
Actualités sur l’immunothérapie en pathologie des voies aérodigestives supérieures
Sophie Outh-Gauer, Christophe Le Tourneau, Chloé Broudin, Florian Scotte, Hélène Roussel, Stéphane Hans, Marion Mandavit, Eric Tartour, Cécile Badoual
Annales de Pathologie.2017; 37(1): 79. CrossRef
Overview of Sinonasal and Ventral Skull Base Malignancy Management
Peter F. Svider, Michael Setzen, Soly Baredes, James K. Liu, Jean Anderson Eloy
Otolaryngologic Clinics of North America.2017; 50(2): 205. CrossRef
PD-L1 expression and CD8+ infiltration shows heterogeneity in Juvenile Recurrent Respiratory Papillomatosis
Tingyu Liu, Max Greenberg, Carissa Wentland, Brandon Sepe, Sarah Bowe, Gillian Diercks, Tiffany Huynh, Mari Mino-Kenudson, Richard Schlegel, David Kodack, Cyril Benes, Jeffrey Engelman, Christopher Hartnick
International Journal of Pediatric Otorhinolaryngo.2017;[Epub] CrossRef
Programmed cell death ligand 1 as a biomarker in head and neck cancer
Sara I. Pai, William C. Faquin
Cancer Cytopathology.2017; 125(7): 529. CrossRef
Turning the tide: Clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck
Astrid De Meulenaere, Tijl Vermassen, Sandrine Aspeslagh, Wouter Huvenne, Jo Van Dorpe, Liesbeth Ferdinande, Sylvie Rottey
Oral Oncology.2017; 70: 34. CrossRef
Time to change perspectives on HPV in oropharyngeal cancer. A systematic review of HPV prevalence per oropharyngeal sub-site the last 3 years
Linnea Haeggblom, Torbjörn Ramqvist, Massimo Tommasino, Tina Dalianis, Anders Näsman
Papillomavirus Research.2017; 4: 1. CrossRef
The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)
Panagiotis Balermpas, Franz Rödel, Mechthild Krause, Annett Linge, Fabian Lohaus, Michael Baumann, Inge Tinhofer, Volker Budach, Ali Sak, Martin Stuschke, Eleni Gkika, Anca-Ligia Grosu, Amir Abdollahi, Jürgen Debus, Stefan Stangl, Ute Ganswindt, Claus Bel
International Journal of Cancer.2017; 141(3): 594. CrossRef
Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: A systematic review and meta-analysis
Ji Li, Ping Wang, Youliang Xu, Jung Weon Lee
PLOS ONE.2017; 12(6): e0179536. CrossRef
Association between PD-L1 and HPV status and the prognostic value for HPV treatment in premalignant cervical lesion patients
Feng Yang-Chun, Cheng Zhen-Zhen, Huang Yan-Chun, Ma Xiu-Min
Medicine.2017; 96(25): e7270. CrossRef
Expressions of programmed death (PD)‐1 and PD‐1 ligand (PD‐L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status
Wen Yang, Yan‐Ping Lu, Yi‐Zhou Yang, Jia‐Rui Kang, Yi‐Duo Jin, Hong‐Wei Wang
Journal of Obstetrics and Gynaecology Research.2017; 43(10): 1602. CrossRef
Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study
Chiun Hsu, Se-Hoon Lee, Samuel Ejadi, Caroline Even, Roger B. Cohen, Christophe Le Tourneau, Janice M. Mehnert, Alain Algazi, Emilie M.J. van Brummelen, Sanatan Saraf, Pradeep Thanigaimani, Jonathan D. Cheng, Aaron R. Hansen
Journal of Clinical Oncology.2017; 35(36): 4050. CrossRef
Human papillomavirus-related oropharyngeal cancer
M. Taberna, M. Mena, M.A. Pavón, L. Alemany, M.L. Gillison, R. Mesía
Annals of Oncology.2017; 28(10): 2386. CrossRef
Circulating tumour cell PD-L1 test for head and neck cancers
Arutha Kulasinghe, Liz Kenny, Chamindie Punyadeera
Oral Oncology.2017; 75: 6. CrossRef
Tumor PD-L1 status and CD8+ tumor-infiltrating T cells: markers of improved prognosis in oropharyngeal cancer
Astrid De Meulenaere, Tijl Vermassen, Sandrine Aspeslagh, Philippe Deron, Fréderic Duprez, Debby Laukens, Jo Van Dorpe, Liesbeth Ferdinande, Sylvie Rottey
Oncotarget.2017; 8(46): 80443. CrossRef
Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma
Axel Lechner, Hans Schlößer, Sacha I. Rothschild, Martin Thelen, Sabrina Reuter, Peter Zentis, Alexander Shimabukuro-Vornhagen, Sebastian Theurich, Kerstin Wennhold, Maria Garcia-Marquez, Lars Tharun, Alexander Quaas, Astrid Schauss, Jörg Isensee, Tim Huc
Oncotarget.2017; 8(27): 44418. CrossRef
Tumoral PD-L1 expression defines a subgroup of poor-prognosis vulvar carcinomas with non-viral etiology
Thomas Hecking, Thore Thiesler, Cynthia Schiller, Jean-Marc Lunkenheimer, Tiyasha H. Ayub, Andrea Rohr, Mateja Condic, Mignon-Denise Keyver-Paik, Rolf Fimmers, Jutta Kirfel, Walther Kuhn, Glen Kristiansen, Kirsten Kübler
Oncotarget.2017; 8(54): 92890. CrossRef
Evaluation of PD-L1 Expression in Tumor Tissue of Patients with Lung Carcinoma and Correlation with Clinical and Demographic Data
Gustavo Dix Junqueira Pinto, Luciano de Souza Viana, Cristovam Scapulatempo Neto, Sérgio Vicente Serrano
Journal of Immunology Research.2016; 2016: 1. CrossRef
Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma
Marlon C. Rebelatto, Anita Midha, Amita Mistry, Constantine Sabalos, Nicole Schechter, Xia Li, Xiaoping Jin, Keith E. Steele, Paul B. Robbins, John A. Blake-Haskins, Jill Walker
Diagnostic Pathology.2016;[Epub] CrossRef
Current clinical immunotherapeutic approaches for head and neck cancer
Carolina Soto Chervin, Bruce Brockstein
F1000Research.2016; 5: 803. CrossRef
PD-L1 expression in tonsillar cancer is associated with human papillomavirus positivity and improved survival: implications for anti-PD1 clinical trials
Angela M Hong, Ricardo E Vilain, Sarah Romanes, Jean Yang, Elizabeth Smith, Deanna Jones, Richard A Scolyer, C Soon Lee, Mei Zhang, Barbara Rose
Oncotarget.2016; 7(47): 77010. CrossRef

17,375 View
346 Download
111 Web of Science
104 Crossref

First
Prev
Page of 1
Next
Last

Search